Anavex Life Sciences Corp (AVXL)

[MayoMobile]

I think I just needed a day or two to really digest the presentation and be sure I was doing it accurately.

I standby all written analysis on: https://www.sotcanalytics.com/special-edition-ctad-2022

I had minor errors on the 'data' slide from the post-CTAD video. For example I note that ADCS-ADL improved +3.5 points from baseline. But this isn't really the full story - patients had a vastly greater chance of improving +3.5 points (which is clinically meaningful) over baseline, over placebo group.

So really, my written explanation is a more clear and accurate representation of what was reported.

Going forward, I am compiling a good deal of evidence which supports the reason for Anavex's trial design, and topline readout methodology - specifically, I believe they were being mindful of requirements and expectations for EMA approval. Will make a post on that sometime soon.